ESPR FY 2013 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$501M

FY 2013 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$5.0B

Gross Profit

$5.0B100.0% margin

Operating Income

-$23M-0.5% margin

Net Income

-$26M-0.5% margin

EPS (Diluted)

$-1.70

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$78M

Total Liabilities

$4M

Stockholders' Equity

$74M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.0B	$0	—
Gross Profit	$5.0B	$0	—
Operating Income	-$23M	-$10M	-123.0%
Net Income	-$26M	-$12M	-122.2%